READ THE FULL APVO RESEARCH REPORT
We are initiating coverage of Aptevo Therapeutics Inc. (NASDAQ: APVO) with a valuation of $30.00. Aptevo is a clinical-stage biotechnology company developing multispecific immunotherapies designed to harness the immune system to selectively target and eliminate cancer cells. Aptevo’s pipeline includes both hematologic malignancy and solid tumor programs built upon the company’s proprietary ADAPTIR™ and ADAPTIR-FLEX™ platforms, which are engineered to generate bispecific and trispecific immune-engaging proteins with customizable functional characteristics.
The company’s lead program, mipletamig, is a CD123 x CD3 bispecific T cell engager being evaluated for frontline acute myeloid leukemia (AML) in combination with venetoclax and azacitidine. Clinical data generated to date suggest that mipletamig may offer an attractive balance between efficacy and safety. Mipletamig is designed to reduce the risk of cytokine release syndrome (CRS), an often severe treatment toxicity and complication that can occur following therapy with bispecific antibodies.
Aptevo’s broader pipeline includes several additional immune-engaging candidates targeting clinically validated tumor antigens and immune co-stimulatory pathways, including PSMA, Nectin-4, PD-L1, CD40, 4-1BB, and OX40. Importantly, many of these candidates incorporate the company’s proprietary CRIS-7-derived CD3 binding domain, which management believes may contribute to a differentiated safety profile relative to competing CD3-engaging approaches.
Mipletamig Demonstrates Encouraging Frontline AML Data: Clinical data from frontline AML patients treated with mipletamig in combination with venetoclax and azacitidine demonstrated an 87% clinical benefit rate and 79% CR/CRi rate among evaluable patients. Importantly, no CRS has been observed among the frontline patient population through Cohort 5 of the RAINIER study.
Proprietary CRIS-7-Derived CD3 Binding Domain May Provide Differentiation: One of the most significant challenges associated with CD3-engaging bispecifics is CRS. Aptevo’s proprietary CRIS-7-derived CD3 binding domain was specifically engineered to potentially reduce cytokine release while preserving anti-tumor activity.
ADAPTIR and ADAPTIR-FLEX Provide Broad Platform Utility: Aptevo’s platform technologies enable the design of mono-, bi-, and trispecific therapeutics with customizable valency, immune activation, and half-life characteristics. This modularity may allow the company to efficiently generate multiple product candidates across diverse oncology indications.
Significant Unmet Need Remains Across Target Indications: AML remains an area of substantial unmet medical need despite the introduction of venetoclax-based frontline regimens. Similarly, solid tumor immunotherapy continues to face major challenges related to tumor localization, an immune suppressive tumor microenvironment (TME), and systemic toxicity.
Progression into Radiopharmaceutical Development with Niowave Collaboration: In May 2026, Aptevo announced a 50/50 collaboration with Niowave, Inc. to develop up to three radiopharmaceutical oncology programs, with Aptevo initially contributing Nectin-4 constructs. This collaboration is an important continuation of Aptevo’s work with an emerging treatment paradigm.
Experienced Leadership Team with Deep Institutional Knowledge: Aptevo’s senior management team has remained remarkably stable over time, with CEO Jeff Lam and CFO Daphne King serving since the company’s formation, and several other key executives contributing more than four years. We believe this continuity has fostered a cohesive operating culture and provided valuable institutional knowledge as the company has advanced both its ADAPTIR platform technologies and clinical pipeline.
Valuation
We value Aptevo using a probability-adjusted discounted cash flow model that takes into account revenues from mipletamig and ALG-AVP-527, along with a modest contribution from the underlying ADAPTIR and ADAPTIR-FLEX platform technologies and the Niowave collaboration. Given the early stage of development of the remainder of the pipeline, including APVO603, APVO442, APVO711, APVO451, APVO452, and APVO455, we do not currently assign explicit valuation to these programs.
For mipletamig, we estimate there are approximately 25,000 newly diagnosed AML patients annually in the U.S. and major European markets that fall within the addressable population targeted by mipletamig. Given the encouraging remission rates reported from the ongoing RAINIER study, including high rates of MRD-negative remission and the absence of CRS reported to date, we believe mipletamig has the potential to capture meaningful market share if future studies continue to demonstrate a differentiated balance of equity and tolerability.
We assume peak global market penetration of approximately 30% within the frontline unfit AML population and annual net pricing of approximately $125,000 per patient in the U.S. and $65,000 in the E.U., which results in projected peak revenues of approximately $1.0 billion seven years after approval in 2030. Using a probability of success of 33% and a 13% discount rate leads to a net present value for mipletamig of approximately $258 million.
For ALG.APV-527, even though the asset is much earlier in development than mipletamig, we believe it contributes meaningful strategic value as it serves not only as an individual therapeutic program but also as a clinical validation opportunity for the broader ADAPTIR-FLEX platform. Given the large potential commercial opportunities across multiple solid tumor indications, we model peak annual revenues of approximately $1.5 billion seven years after approval in 2032. Using a probability of success of 10% and a 13% discount rate leads to a net present value for ALG.APV-527 of $30 million.
In addition to the clinical stage assets, we believe the ADAPTIR and ADAPTIR-FLEX platforms and the Niowave collaboration possess independent strategic value based on the existence of two clinical stage molecules, a broad intellectual property portfolio, multiple partnered development programs, and the potential for future licensing, collaboration, and business development opportunities. While we do not currently assign significant value to the company’s preclinical assets, we assign a value of $50 million to the underlying platform technologies and Niowave partnership opportunity.
Combining the net present value for mipletamig, ALG.AVP-527, and the platform/partnering opportunities, along with the current cash position and potential cash from warrant exercises leads to a net present value for Aptevo of $361 million. Dividing by the fully diluted share count (approximately 1.9 million) plus an additional 10 million shares to account for additional financings leads to a valuation of $30 per share.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
